ERBB2 and breast carcinoma: On 19 July 2023, this indication was expanded to include adult patients with unresectable locally advanced or metastatic HR-positive, HER2-negative or low breast cancer who have received endocrine-based therapy and at least two additional systemic therapies in the metastatic setting [17].